Amgen’s second-quarter profit slipped 7.6 percent as a series of restructuring and other charges further stunted a second quarter already hit by a continued decline in anemia drug sales. But the results topped Wall Street forecasts after excluding the charges, and the stock reached its highest point in more than a year Monday, buoyed by positive study results on the company’s next possible blockbuster, the osteoporosis drug Denosumab. The stock rose $6.56, or 12.2 percent, to close at $60.48, and rose a further $1.22 to $61.70 in after-hours trading. During the second quarter ended June 30, the company earned $941 million, or 87 cents a share, compared with $1.02 billion, or 90 cents a share, a year earlier. Revenue rose just under 1 percent to $3.76 billion from $3.73 billion.
